ITCI Aug 2024 60.000 call
| Previous close | 16.19 |
| Open | 16.19 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 60.00 |
| Expiry date | 2024-08-16 |
| Day's range | 16.19 - 16.19 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Investor's Business DailyIntra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win
Intra-Cellular has a big opportunity in depression treatment, an analyst said Tuesday as the biotech stock surged on test results.
GlobeNewswireIntra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (4.5 point reduction v. placebo; p<0.0001; Cohen’s d effect size (ES)=0.56) Lumateperone 42 mg also met the key secondary endpoint of change from baseline at Week 6 on the Clinical Glo
- GlobeNewswire
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 45th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2024 at 10:00 a.m. ET in Miami, FL. The live and archived webcast can be accessed und
